Full-Time

BI Engineer

Posted on 5/11/2025

Amgen

Amgen

10,001+ employees

Develops biologic therapies for serious illnesses

No salary listed

Senior

Hyderabad, Telangana, India

Category
Data Management
Data & Analytics
Required Skills
Power BI
Redshift
BigQuery
SQL
Tableau
Databricks
Looker
Snowflake
Requirements
  • 5 - 8 years of experience in BI development and data visualization, with deep expertise in tools such as Power BI, Tableau, or Looker.
  • Strong knowledge of SQL, data modeling techniques, and BI architecture best practices.
  • Experience working with data warehouses and cloud data platforms
  • Proficiency in building dashboards, KPIs, and executive-level reporting that align with business priorities.
  • Solid understanding of ETL/ELT processes, data pipelines, and integration with BI tools.
  • Strong collaboration skills with the ability to work effectively across engineering, product, finance, and business teams.
  • Excellent communication skills, with a proven ability to translate technical concepts into business value.
Responsibilities
  • Design, develop, and maintain enterprise-grade BI dashboards and reports using tools like Power BI, Tableau, or Looker.
  • Build and optimize semantic models, tabular data structures, and reusable datasets for self-service BI users.
  • Partner with business stakeholders to translate requirements into technical solutions, delivering accurate, relevant, and timely insights.
  • Work closely with data engineering teams to integrate BI solutions into data lake, warehouse, or lakehouse architectures (e.g., Snowflake, Redshift, Databricks, BigQuery).
  • Implement best practices for BI development, including version control, performance optimization, and data governance.
  • Ensure BI solutions are secure, scalable, and aligned with enterprise data governance standards.
  • Mentor junior BI developers and analysts, setting standards for dashboard usability, data visualization, and design consistency.
  • Collaborate with cross-functional teams to promote self-service BI adoption and data literacy throughout the organization.
  • Monitor BI performance, usage, and adoption, providing continuous improvements and training to enhance impact.
Desired Qualifications
  • Experience in cloud platforms (AWS, Azure, or GCP) and modern data stack environments.
  • Familiarity with data governance, data cataloging, metadata management, and access control.
  • Exposure to Agile methodologies, CI/CD for BI, and DevOps practices.
  • BI or data certifications (e.g., Microsoft Certified: Power BI Data Analyst, Tableau Certified Professional).

Amgen develops medicines aimed at treating serious illnesses, focusing on biotechnology. The company researches, develops, and sells biologic therapies, which are medicines made from living organisms. These therapies target conditions like cancer, cardiovascular diseases, and autoimmune disorders. Amgen's approach involves a strong commitment to research and development, allowing them to create new treatments and maintain a pipeline of potential therapies. Unlike many competitors, Amgen reinvests a significant portion of its earnings back into R&D, emphasizing its dedication to innovation and patient care. The goal of Amgen is to provide effective therapeutic solutions to patients worldwide.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Amgen's investment in AI aligns with trends in biotechnology innovation.
  • Institutional investments indicate strong market confidence in Amgen's growth.
  • FTC clearance of the Horizon merger may ease future regulatory hurdles.

What critics are saying

  • Competitors' AI-driven drug discovery could outpace Amgen's traditional R&D methods.
  • FTC scrutiny of mergers may complicate Amgen's future growth strategy.
  • Advancements in quantum technologies could pose a competitive threat to Amgen.

What makes Amgen unique

  • Amgen focuses on biologic therapies derived from living organisms.
  • The company has a strong pipeline of potential new therapies in development.
  • Amgen's acquisition of Horizon Therapeutics enhances its rare disease portfolio.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

MarketBeat
Jan 28th, 2024
Factory Mutual Insurance Co. Makes New Investment in Amgen Inc. (NASDAQ:AMGN)

Factory Mutual Insurance Co. purchased a new position in Amgen Inc. (NASDAQ:AMGN - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 53,500 shares of the medical research company's stock, valued at approxim

The Quantum Insider
Jan 16th, 2024
Honeywell Announces the Closing of $300 Million Equity Investment Round for Quantinuum at $5 Billion Pre-Money Valuation

JPMorgan Chase has one of the world's most highly regarded specialist teams working on quantum technologies within the financial services industry and has been working with Quantinuum and its predecessor companies since 2020.

ETF Daily News
Dec 17th, 2023
Northwest Quadrant Wealth Management LLC Invests $237,000 in Amgen Inc. (NASDAQ:AMGN)

Northwest Quadrant Wealth Management LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund bought 883 shares of the medical research company’s stock, valued at approximately $237,000. A number of other institutional investors […]

Horizon Therapeutics
Sep 21st, 2023
Rule 2.7 Announcement: Amgen Inc to Acquire Horizon Therapeutics plc | Horizon Therapeutics plc

The Investor Relations website contains information about Horizon Therapeutics plc's business for stockholders, potential investors, and financial analysts.

BioSpace
Sep 19th, 2023
Amgen-Horizon Merger Clearance a Setback to FTC’s Antitrust Enforcement Plans

The consent agreement struck between the FTC and Amgen and Horizon Therapeutics could have significant implications for ongoing and future M&A challenges, experts told BioSpace.